Kyverna Therapeutics Gains RMAT Designation for Miv-Cel in Progressive Multiple Sclerosis

Kyverna Therapeutics' centralized autologous manufacturing model for miv-cel now carries the weight of a third indication, with FDA RMAT designation granted in August 2026 for non-active secondary progressive multiple sclerosis (naSPMS), a development that sharpens the commercial-scale supply calculus for cell therapy CMOs already tracking the company's stiff person syndrome BLA.

The designation was based on 12-month follow-up data from a Stanford University phase 1 investigator-initiated trial enrolling six patients with progressive MS. Patients received either 33 million or 100 million autologous CD19-targeting CAR T cells following a bendamustine lymphodepleting regimen. Reported biomarker findings showed CAR T-cell expansion in both blood and cerebrospinal fluid, alongside naive B-cell reconstitution consistent with an immune reset mechanism. Disability status outcomes, adverse event rates, and CRS and ICANS grading have not been disclosed; Kyverna has indicated additional Stanford IIT data will be reported in Q4 2026.

For QA directors and manufacturing leads, the RMAT pathway carries concrete operational implications. Designation provides eligibility for rolling and priority review and, critically, increased FDA engagement during development, a channel Kyverna has signaled it will use to shape its naSPMS regulatory strategy, with a development plan expected by early 2027. Miv-cel's manufacturing process, apheresis, ex vivo genetic engineering, and centralized batch release, is already established across the SPS and generalized myasthenia gravis programs, where a Phase 3 registrational trial is currently enrolling. Adding a third indication to that infrastructure raises process validation and capacity planning questions that CMOs supporting autologous cell therapy at commercial scale will need to address in parallel with Kyverna's clinical timeline.

The RMAT designation extends miv-cel's neuroimmunology franchise at a point when the SPS rolling Biologics License Application is already underway under 21 CFR Part 601, meaning Kyverna's manufacturing quality systems are already under regulatory scrutiny. Consistency of the lymphodepletion regimen across indications, particularly the use of bendamustine as an alternative conditioning backbone in the Stanford IIT, will be a reference point for any comparability assessments required as the naSPMS program advances toward a pivotal design.

Kyverna's Q4 2026 data readout from the Stanford IIT, including any safety grading and functional outcome data, will serve as the next measurable checkpoint for assessing whether the naSPMS program can sustain the clinical evidence base that RMAT designation requires to translate into a viable BLA pathway.

Source: CGTLive via cgtlive.com, 20 August 2026.